Informações de Silence Therapeutics PLC

Mais detalhes de Silence Therapeutics PLC Empresa

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.



Código da empresaSLN

Nome da EmpresaSilence Therapeutics PLC

Data de listagemJan 05, 2010

CEOMr. Craig A. Tooman

Número de funcionários116

Tipo de títulosDepository Receipt

Fim do ano fiscalJan 05

Endereço72 Hammersmith Road

CidadeLONDON

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited Kingdom

Código postalW14 8TH

Telefone442034576900

Sitehttps://www.silence-therapeutics.com/

Código da empresaSLN

Data de listagemJan 05, 2010

CEOMr. Craig A. Tooman

Executivos da empresa Silence Therapeutics PLC



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

Ms. Gem Hopkins

Head of IR and Corporate Communications

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

Sem dados

Por RegiãoUSD

Nome

Receita

Proporção

United Kingdom

43.11M

99.67%

Germany

144.00K

0.33%

USA

0.00

0.00%

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.92%

Outro

54.54%

Investidores

Proporção

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.92%

Outro

54.54%

Tipos de investidores

Investidores

Proporção

Individual Investor

24.38%

Investment Advisor

18.45%

Investment Advisor/Hedge Fund

10.19%

Hedge Fund

4.99%

Venture Capital

3.35%

Research Firm

3.17%

Private Equity

2.05%

Bank and Trust

0.02%

Outro

33.40%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

138

19.95M

42.23%

-14.75M

2025Q2

131

33.68M

71.31%

-14.18M

2025Q1

133

31.94M

67.63%

-14.00M

2024Q4

128

31.43M

66.56%

-10.23M

2024Q3

111

35.93M

77.05%

-5.19M

2024Q2

96

34.94M

74.95%

-4.57M

2024Q1

86

35.43M

76.18%

+4.14M

2023Q4

61

30.21M

78.15%

-609.51K

2023Q3

58

32.62M

88.08%

+1.55M

2023Q2

54

31.78M

89.08%

+2.79M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Griffiths (Richard Ian)

11.51M

24.38%

+543.58K

+4.95%

Jun 25, 2025

TCG Crossover Management, LLC

3.03M

6.42%

--

Jun 30, 2025

Invus Public Equities Advisors, LLC

2.91M

6.16%

+121.61K

+4.36%

Jun 30, 2025

Redmile Group, LLC

2.16M

4.58%

-50.17K

-2.27%

Jun 30, 2025

Lombard Odier Asset Management (USA) Corp.

1.85M

3.92%

--

Jun 30, 2025

Morgan Stanley & Co. LLC

1.13M

2.39%

-766.91K

-40.44%

Jun 30, 2025

Vivo Capital, LLC

1.11M

2.34%

--

Jun 30, 2025

Nantahala Capital Management, LLC

1.04M

2.21%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

970.13K

2.05%

-178.46K

-15.54%

Jun 30, 2025

Nextech Invest, Ltd.

952.40K

2.02%

--

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

Virtus LifeSci Biotech Clinical Trials ETF

0.67%

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.01%

ActivePassive International Equity ETF

0%

iShares Biotechnology ETF

0%

Tema Heart & Health ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0.67%

ProShares Ultra Nasdaq Biotechnology

Proporção0.03%

Invesco Nasdaq Biotechnology ETF

Proporção0.03%

SPDR S&P International Small Cap ETF

Proporção0.01%

ActivePassive International Equity ETF

Proporção0%

iShares Biotechnology ETF

Proporção0%

Tema Heart & Health ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados